Mesenchymal stem cells and serelaxin synergistically abrogate established airway fibrosis in an experimental model of chronic allergic airways disease

Mesenchymal stem cells and serelaxin synergistically abrogate established airway fibrosis in an experimental model of chronic allergic airways disease

This study determined if the anti-fibrotic drug, serelaxin (RLN), could augment human bone marrow-derived mesenchymal stem cell (MSC)-mediated reversal of airway remodeling and airway hyperresponsiveness (AHR) associated with chronic allergic airways disease (AAD/asthma). Female Balb/c mice subjecte...

Full description

Bibliographic Details
Main Authors: Simon G. Royce, Matthew Shen, Krupesh P. Patel, Brooke M. Huuskes, Sharon D. Ricardo, Chrishan S. Samuel
Format: Article
Language:English
Published: Elsevier 2015-11-01
Series:Stem Cell Research
Subjects:
Asthma
Airway remodeling
Fibrosis
Mesenchymal stem cells
Serelaxin
Online Access:http://www.sciencedirect.com/science/article/pii/S1873506115001208

Internet

http://www.sciencedirect.com/science/article/pii/S1873506115001208

Similar Items